North America Rapid Diagnostics Market 2021-2031 by Product (Consumables, Analyzers/Instruments), Prescription (Professional, OTC), Platform (Immunoassays, Molecular Detection, Others), Application, End User, and Country: Trend Forecast and Growth Opportunity

December 2022 | 120 pages | ID: NA271E664EF1EN
GMD Research

Abstracts

North America Rapid Diagnostics is projected to grow by 6.5% annually in the forecast period and reach $29,905.4 million by 2031, driven by the growing demand for POC diagnostics, the rising prevalence of chronic diseases coupled with the increasing aging population, the growing necessity for rapid decision making in emergency departments, increase in awareness regarding early diagnosis of disease, and emerging technological innovations.

Highlighted with 28 tables and 61 figures, this 120-page report “North America Rapid Diagnostics Market 2021-2031 by Product (Consumables, Analyzers/Instruments), Prescription (Professional, OTC), Platform (Immunoassays, Molecular Detection, Others), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire North America Rapid Diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America Rapid Diagnostics market in every aspect of the classification from perspectives of Product, Prescription, Platform, Application, End User, and Country.

Based on Product, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Consumables
• Analyzers/Instruments

Based on Prescription, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Professional Diagnostics
• OTC Based Testing

By Platform, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Immunoassays
• Lateral Flow Assays
• Serological Assays
• Other Immunoassays
• Molecular Detection
• Polymerase Chain Reaction (PCR)
• Other Molecular Detection Tests
• Other Platforms

By Application, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Blood Glucose Testing
• Cardiometabolic Testing
• Infectious Disease Testing
• COVID-19 Testing
• Healthcare-associated Infections (HAI) Testing
• Hepatitis Testing
• Tropical Diseases Testing
• HIV Testing
• Influenza Testing
• Sexually Transmitted Diseases (STD) Testing
• Other Infectious Diseases Testing
• Blood Coagulation Testing
• Hematology Testing
• Cancer Testing
• Drug Abuse Testing
• Pregnancy & Fertility Testing
• Other Applications

By End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.

• Hospitals & Clinics
• Laboratories
• Individuals/Homecare
• Other End Users

Geographically, the following national/local markets are fully investigated:

• U.S.
• Canada
• Mexico

For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product, Prescription and Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Selected Key Players:

Abbott Diagnostics

ACON Laboratories

Becton Dickinson and Co.

BioMйrieux S.A.

Bio-Rad Laboratories, Inc.

Chembio Diagnostic Systems

Danaher Corp.

F. Hoffmann La Roche Ltd.

GlySens Inc.

Meridian Bioscience Inc.

OraSure Technologies Inc.

Siemens Healthineers AG

Thermo Fisher Scientific Inc.

Trinity Biotech Plc

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

1.1 Industry Definition and Research Scope
  1.1.1 Industry Definition
  1.1.2 Research Scope
1.2 Research Methodology
  1.2.1 Overview of Market Research Methodology
  1.2.2 Market Assumption
  1.2.3 Secondary Data
  1.2.4 Primary Data
  1.2.5 Data Filtration and Model Design
  1.2.6 Market Size/Share Estimation
  1.2.7 Research Limitations
1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

2.1 Market Size and Forecast
  2.1.1 Impact of COVID-19 on World Economy
  2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 SEGMENTATION OF NORTH AMERICA MARKET BY PRODUCT

3.1 Market Overview by Product
3.2 Consumables
3.3 Analyzers/Instruments

4 SEGMENTATION OF NORTH AMERICA MARKET BY PRESCRIPTION

4.1 Market Overview by Prescription
4.2 Professional Diagnostics
4.3 OTC Based Testing

5 SEGMENTATION OF NORTH AMERICA MARKET BY PLATFORM

5.1 Market Overview by Platform
5.2 Immunoassays
  5.2.1 Lateral Flow Assays
  5.2.2 Serological Assays
  5.2.3 Other Immunoassays
5.3 Molecular Detection
  5.3.1 Polymerase Chain Reaction (PCR)
  5.3.2 Other Molecular Detection Tests
5.4 Other Platforms

6 SEGMENTATION OF NORTH AMERICA MARKET BY APPLICATION

6.1 Market Overview by Application
6.2 Blood Glucose Testing
6.3 Cardiometabolic Testing
6.4 Infectious Disease Testing
  6.4.1 COVID-19 Testing
  6.4.2 Healthcare-associated Infections (HAI) Testing
  6.4.3 Hepatitis Testing
  6.4.4 Tropical Diseases Testing
  6.4.5 HIV Testing
  6.4.6 Influenza Testing
  6.4.7 Sexually Transmitted Diseases (STD) Testing
  6.4.8 Other Infectious Diseases Testing
6.5 Blood Coagulation Testing
6.6 Hematology Testing
6.7 Cancer Testing
6.8 Drug Abuse Testing
6.9 Pregnancy & Fertility Testing
6.10 Other Applications

7 SEGMENTATION OF NORTH AMERICA MARKET BY END USER

7.1 Market Overview by End User
7.2 Hospitals & Clinics
7.3 Laboratories
7.4 Individuals/Homecare
7.5 Other End Users

8 NORTH AMERICA MARKET 2021-2031 BY COUNTRY

8.1 Overview of North America Market
8.2 U.S.
8.3 Canada
8.4 Mexico

9 COMPETITIVE LANDSCAPE

9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
Abbott Diagnostics
ACON Laboratories
Becton Dickinson and Co.
BioMйrieux S.A.
Bio-Rad Laboratories, Inc.
Chembio Diagnostic Systems
Danaher Corp.
F. Hoffmann La Roche Ltd.
GlySens Inc.
Meridian Bioscience Inc.
OraSure Technologies Inc.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Trinity Biotech Plc
RELATED REPORTS

List Of Tables

LIST OF TABLES:

Table 1. Snapshot of North America Rapid Diagnostics Market in Balanced Perspective, 2021-2031
Table 2. World Economic Outlook, 2021-2031
Table 3. World Economic Outlook, 2021-2023
Table 4. World Health Spending by Region, $ bn, 2013-2020
Table 5. Main Product Trends and Market Opportunities in North America Rapid Diagnostics Market
Table 6. North America Rapid Diagnostics Market by Product, 2021-2031, $ mn
Table 7. North America Rapid Diagnostics Market by Prescription, 2021-2031, $ mn
Table 8. North America Rapid Diagnostics Market by Platform, 2021-2031, $ mn
Table 9. North America Rapid Diagnostics Market: Immunoassays by Type, 2021-2031, $ mn
Table 10. North America Rapid Diagnostics Market: Molecular Detection by Type, 2021-2031, $ mn
Table 11. North America Rapid Diagnostics Market by Application, 2021-2031, $ mn
Table 12. North America Rapid Diagnostics Market: Infectious Disease Testing by Type, 2021-2031, $ mn
Table 13. North America Rapid Diagnostics Market by End User, 2021-2031, $ mn
Table 14. North America Rapid Diagnostics Market by Country, 2021-2031, $ mn
Table 15. U.S. Rapid Diagnostics Market by Product, 2021-2031, $ mn
Table 16. U.S. Rapid Diagnostics Market by Prescription, 2021-2031, $ mn
Table 17. U.S. Rapid Diagnostics Market by Application, 2021-2031, $ mn
Table 18. Canada Rapid Diagnostics Market by Product, 2021-2031, $ mn
Table 19. Canada Rapid Diagnostics Market by Prescription, 2021-2031, $ mn
Table 20. Canada Rapid Diagnostics Market by Application, 2021-2031, $ mn
Table 21. Mexico Rapid Diagnostics Market by Product, 2021-2031, $ mn
Table 22. Mexico Rapid Diagnostics Market by Prescription, 2021-2031, $ mn
Table 23. Mexico Rapid Diagnostics Market by Application, 2021-2031, $ mn
Table 24. Rapid Diagnostic Analyzers by Vendor
Table 25. Recent Product Launches, 2018-2021
Table 26. Abbott Diagnostics: Company Snapshot
Table 27. Abbott Diagnostics: Business Segmentation
Table 28. Abbott Diagnostics: Product Portfolio

List Of Figures

LIST OF FIGURES:

Figure 1. Research Method Flow Chart
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031
Figure 4. North America Rapid Diagnostics Market, 2021-2031, $ mn
Figure 5. Impact of COVID-19 on Business
Figure 6. Primary Drivers and Impact Factors of North America Rapid Diagnostics Market
Figure 7. Leading Causes of Death in the World, 2000 and 2019, million
Figure 8. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million
Figure 9. World Population 65 and Over, % of Total Population, 1950-2060
Figure 10. Primary Restraints and Impact Factors of North America Rapid Diagnostics Market
Figure 11. Investment Opportunity Analysis
Figure 12. Porter’s Fiver Forces Analysis of North America Rapid Diagnostics Market
Figure 13. Breakdown of North America Rapid Diagnostics Market by Product, 2021-2031, % of Revenue
Figure 14. North America Addressable Market Cap in 2022-2031 by Product, Value ($ mn) and Share (%)
Figure 15. North America Rapid Diagnostics Market by Product: Consumables, 2021-2031, $ mn
Figure 16. North America Rapid Diagnostics Market by Product: Analyzers/Instruments, 2021-2031, $ mn
Figure 17. Breakdown of North America Rapid Diagnostics Market by Prescription, 2021-2031, % of Sales Revenue
Figure 18. North America Addressable Market Cap in 2022-2031 by Prescription, Value ($ mn) and Share (%)
Figure 19. North America Rapid Diagnostics Market by Prescription: Professional Diagnostics, 2021-2031, $ mn
Figure 20. North America Rapid Diagnostics Market by Prescription: OTC Based Testing, 2021-2031, $ mn
Figure 21. Breakdown of North America Rapid Diagnostics Market by Platform, 2021-2031, % of Sales Revenue
Figure 22. North America Addressable Market Cap in 2022-2031 by Platform, Value ($ mn) and Share (%)
Figure 23. North America Rapid Diagnostics Market by Platform: Immunoassays, 2021-2031, $ mn
Figure 24. North America Rapid Diagnostics Market by Immunoassays: Lateral Flow Assays, 2021-2031, $ mn
Figure 25. North America Rapid Diagnostics Market by Immunoassays: Serological Assays, 2021-2031, $ mn
Figure 26. North America Rapid Diagnostics Market by Immunoassays: Other Immunoassays, 2021-2031, $ mn
Figure 27. North America Rapid Diagnostics Market by Platform: Molecular Detection, 2021-2031, $ mn
Figure 28. North America Rapid Diagnostics Market by Molecular Detection: Polymerase Chain Reaction (PCR), 2021-2031, $ mn
Figure 29. North America Rapid Diagnostics Market by Molecular Detection: Other Molecular Detection Tests, 2021-2031, $ mn
Figure 30. North America Rapid Diagnostics Market by Platform: Other Platforms, 2021-2031, $ mn
Figure 31. Breakdown of North America Rapid Diagnostics Market by Application, 2021-2031, % of Revenue
Figure 32. North America Addressable Market Cap in 2022-2031 by Application, Value ($ mn) and Share (%)
Figure 33. North America Rapid Diagnostics Market by Application: Blood Glucose Testing, 2021-2031, $ mn
Figure 34. North America Rapid Diagnostics Market by Application: Cardiometabolic Testing, 2021-2031, $ mn
Figure 35. North America Rapid Diagnostics Market by Application: Infectious Disease Testing, 2021-2031, $ mn
Figure 36. North America Rapid Diagnostics Market by Infectious Disease Testing: COVID-19 Testing, 2021-2031, $ mn
Figure 37. North America Rapid Diagnostics Market by Infectious Disease Testing: Healthcare-associated Infections (HAI) Testing, 2021-2031, $ mn
Figure 38. North America Rapid Diagnostics Market by Infectious Disease Testing: Hepatitis Testing, 2021-2031, $ mn
Figure 39. North America Rapid Diagnostics Market by Infectious Disease Testing: Tropical Diseases Testing, 2021-2031, $ mn
Figure 40. North America Rapid Diagnostics Market by Infectious Disease Testing: HIV Testing, 2021-2031, $ mn
Figure 41. North America Rapid Diagnostics Market by Infectious Disease Testing: Influenza Testing, 2021-2031, $ mn
Figure 42. North America Rapid Diagnostics Market by Infectious Disease Testing: Sexually Transmitted Diseases (STD) Testing, 2021-2031, $ mn
Figure 43. North America Rapid Diagnostics Market by Infectious Disease Testing: Other Infectious Diseases Testing, 2021-2031, $ mn
Figure 44. North America Rapid Diagnostics Market by Application: Blood Coagulation Testing, 2021-2031, $ mn
Figure 45. North America Rapid Diagnostics Market by Application: Hematology Testing, 2021-2031, $ mn
Figure 46. North America Rapid Diagnostics Market by Application: Cancer Testing, 2021-2031, $ mn
Figure 47. North America Rapid Diagnostics Market by Application: Drug Abuse Testing, 2021-2031, $ mn
Figure 48. North America Rapid Diagnostics Market by Application: Pregnancy & Fertility Testing, 2021-2031, $ mn
Figure 49. North America Rapid Diagnostics Market by Application: Other Applications, 2021-2031, $ mn
Figure 50. Breakdown of North America Rapid Diagnostics Market by End User, 2021-2031, % of Revenue
Figure 51. North America Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%)
Figure 52. North America Rapid Diagnostics Market by End User: Hospitals & Clinics, 2021-2031, $ mn
Figure 53. North America Rapid Diagnostics Market by End User: Laboratories, 2021-2031, $ mn
Figure 54. North America Rapid Diagnostics Market by End User: Individuals/Homecare, 2021-2031, $ mn
Figure 55. North America Rapid Diagnostics Market by End User: Other End Users, 2021-2031, $ mn
Figure 56. Breakdown of North America Rapid Diagnostics Market by Country, 2021 and 2031, % of Revenue
Figure 57. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%)
Figure 58. U.S. Rapid Diagnostics Market, 2021-2031, $ mn
Figure 59. Canada Rapid Diagnostics Market, 2021-2031, $ mn
Figure 60. Rapid Diagnostics Market in Mexico, 2021-2031, $ mn
Figure 61. Growth Stage of North America Rapid Diagnostics Industry over the Forecast Period